In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8+ T cell responses

Journal of Clinical Investigation

Volumn 111, Issue 11, 2003, Pages 1673-1681

  Esslinger, Christoph ^a,c   Chapatte, Laurence ^a   Finke, Daniela ^b   Miconnet, Isabelle ^b,d   Guillaume, Philippe ^a   MacDonald, H Robson ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b SWISS INST FOR EXP CANCER RESEARCH   (Switzerland)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

^d INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; LENTIVIRUS VECTOR; T LYMPHOCYTE ANTIGEN; TUMOR VACCINE; EPITOPE; GREEN FLUORESCENT PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR; MART1 ANTIGEN; OLIGONUCLEOTIDE; PEPTIDE; PHOTOPROTEIN; TUMOR ANTIGEN; TUMOR PROTEIN; VACCINE;

ANIMAL CELL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG TARGETING; IMMUNE RESPONSE; LYMPH NODE; LYMPHOID ORGAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; T LYMPHOCYTE; VACCINATION; ANIMAL; BIOLOGICAL MODEL; BONE MARROW; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FREE SYSTEM; CELL MOTION; CHEMISTRY; CPG ISLAND; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; LENTIVIRINAE; METABOLISM; POLYMERASE CHAIN REACTION; TIME; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, NEOPLASM; BONE MARROW; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL MOVEMENT; CELL-FREE SYSTEM; CPG ISLANDS; DENDRITIC CELLS; EPITOPES; FLOW CYTOMETRY; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNOTHERAPY; LENTIVIRUS; LUMINESCENT PROTEINS; MICE; MICE, TRANSGENIC; MICROSCOPY, FLUORESCENCE; MODELS, GENETIC; NEOPLASM PROTEINS; OLIGONUCLEOTIDES; PEPTIDES; POLYMERASE CHAIN REACTION; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS; VACCINES;

EID: 0038819053     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200317098     Document Type: Article

References (41)

1. Zitvogel, L., et al. 1996. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med. 183:87-97.
2. Nestle, F.O., et al. 1998. Vaccination of melanoma patients with peptideor tumor lysate-pulsed dendritic cells. Nat. Med. 4:328-332.
3. Thurner, B., et al. 1999. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190:1669-1678.
4. Brossart, P., Goldrath, A.W., Butz, E.A., Martin, S., and Bevan, M.J. 1997. Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL. J. Immunol. 158:3270-3276.
5. Song, W., et al. 1997. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J. Exp. Med. 186:1247-1256.
6. Germain, R.N., and Margulies, D.H. 1993. The biochemistry and cell biology of antigen processing and presentation. Annu. Rev. Immunol. 11:403-450.
7. Rosenberg, S.A., et al. 1998. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 1 melanoma antigens. J. Natl. Cancer Inst. 90:1894-1900.
8. Esslinger, C., Romero, P., and MacDonald, H.R. 2002. Efficient transduction of dendritic cells and induction of a T-cell response by third-generation lentivectors. Hum. Gene Ther. 13:1091-1100.
9. Gruber, A., Kan-Mitchell, J., Kuhen, K.L., Mukai, T., and Wong-Staal, F. 2000. Dendritic cells transduced by multiply deleted HIV-1 vectors exhibit normal phenotypes and functions and elicit an HIV-specific cytotoxic T-lymphocyte response in vitro. Blood. 96:1327-1333.
10. Zarei, S., Leuba, F., Arrighi, J.F., Hauser, C., and Piguet, V. 2002. Transduction of dendritic cells by antigen-encoding lentiviral vectors permits antigen processing and MHC class I-dependent presentation. J. Allergy Clin. Immunol. 109:988-994.
11. Salmon, P., et al. 2001. Transduction of CD34+ cells with lentiviral vectors enables the production of large quanlifies of transgene-expressing immature and mature dendritic cells. J. Gene Med. 3:311-320.
12. Zufferey, R., et al. 1998. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 72:9873-9880.
13. Dill, O., Kievits, F., Koch, S., Ivanyi, P., and Hammerling, G.J. 1988. Immunological function of HLA-C antigens in HLA-Cw3 transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 85:5664-5668.
14. Vitiello, A., Marchesini, D., Furze, J., Sherman, L.A., and Chesnut, R.W. 1991. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J. Exp. Med. 173:1007-1015.
15. Maryanski, J.L., Accolla, R.S., and Jordan, B. 1986. H2-restricted recognition of cloned HLA class I gene products expressed in mouse cells. J. Immunol. 136:4340-4347.
16. Bour, H., Horvath, C., Lurquin, C., Cerottini, J.C., and MacDonald, H.R. 1998. Differential requirement for CD4 help in the development of an antigen-specific CD8+ T cell response depending on the route of immunization. J. Immunol. 160:5522-5529.
17. Maryanski, J.L., Pala, P., Corradin, G., Jordan, B.R., and Cerottini, J.C. 1986. H-2-restricted cytolytic T cells specific for HLA can recognize a synthetic HLA pepcide. Nature. 324:578-579.
18. Valmori, D., et al. 1998. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J. Immunol. 160:1750-1758.
19. Dull, T., et al. 1998. A third-generation lentivirus vector with a conditional packaging system. J. Virol. 72:8463-8471.
20. Inaba, K., et al. 1992. Generadon of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176:1693-1702.
21. Barchet, W., et al. 2000. Direct quantitation of rapid elimination of viral antigen-positive lymphocytes by antiviral CD8(+) T cells in vivo. Eur. J. Immunol. 30:1356-1363.
22. Sigal, L.J., Crotty, S., Andino, R., and Rock, K.L. 1999. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature. 398:77-80
23. Sigal, L.J., and Rock, K.L. 2000. Bone marrow-derived APCs are required for the generation of cytotoxic T lymphocyte responses to viruses and use transporter associated with antigen presentation (TAP)-dependent and -independent pathways of antigen presentation. J. Exp. Med. 192:1143-1150.
24. Bour, H., Michielin, O., Bousso, P., Cerottini, J.C., and MacDonald, H.R. 1999. Dramatic influence of V beta gene polymorphism on an antigen-specific CD8+ T cell response in vivo. J. Immunol. 162:4647-4656.
25. MacDonald, H.R., Casanova, J.L., Maryanski, J.L., and Cerottini, J.C. 1993. Oligoclonal expansion of major histocompatibility complex class I-restricted cytolytic T lymphocytes during a primary immune response in vivo: direct monitoring by flow cytometry and polymerase chain reaction. J Exp. Med. 177:1487-1492.
26. Miconnet, I., et al. 2002. CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide. J. Immunol. 168:1212-1218.
27. Coulie, P.G., et al. 1994. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180:35-42.
28. Kawakami, Y., et al. 1994. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 180:347-352.
29. Malek, T.R. 2002. T helper cells, IL-2 and the generation of cytotoxic T-cell responses. Trends Immunol. 23:465-467.
30. Buller, R.M., Holmes, K.L., Hugin, A., Frederickson, T.N., and Morse, H.C., III. 1987. Induction of cytotoxic T-cell responses in vivo in the absence of CD4 helper cells. Nature. 328:77-79.
31. Rosenberg, S.A., et al. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4:321-327.
32. Yu, Z., and Restifo, N.P. 2002. Cancer vaccines: progress reveals new complexities. J. Clin. Invest. 110:289-294. doi:10.1172/JCI200216216.
33. Vanden Driessche, T., et al. 2002. Lentiviral vectors containing the human immunodeficiency virus type-1 central polypurine tract can efficiently transduce nondividing hepatocytes and antigen-presenting cells in vivo. Blood. 100:813-822.
34. Folienzi, A., Ailles, L.E., Bakovic, S., Geuna, M., and Naldini, L. 2000. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat. Genet. 25:217-222.
35. Matsuno, K., Ezaki, T., Kudo, S., and Uehara, Y. 1996. A life stage of particle-laden rat dendritic cells in vivo: their terminal division, active phagocytosis, and translocation from the liver co the draining lymph. J. Exp. Med. 183:1865-1878
36. Ridge, J.P., Di Rosa, F., and Matzinger, P. 1998. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature. 393:474-478.
37. Bennett, S.R., et al. 1998. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature. 393:478-480.
38. Schoenberger, S.P., Toes, R.E., van der Voort, E.I., Offringa, R., and Melief, C.J. 1998. T-cell help for cyrotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 393:480-483.
39. Wang, B., et al. 2001 Multiple paths For activation of naive CD8+ T cells: CD4-independent help. J. Immunol. 167:1283-1289.
40. Mintern, J.D., Davey, G.M., Belz, G.T., Carbone, F.R., and Heath, W.R. 2002. Cutting edge: precursor frequency affects the helper dependence of cytotoxic T cells. J. Immunol. 168:977-980.
41. Firat, H., et al. 2002. Comparative analysis of the CD8(+) T cell repertoires of H-2 class I wild-type/HLA-A2.1 and H-2 class I knockout/HLA-A2.1 transgenic mice. Int. Immunol. 14:925-934.